الفهرس 
coverOnly 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
Reactivation of hepatitis infection is well documented in patients receiving cytotoxic therapy for their haematological malignancies. The chemotherapy courses are interrupted and compromised due to immunosuppression-induced hepatitis flares.
This may result in varying degrees of liver damage, thus precluding appropriate chemotherapy courses and, therefore, increasing the possibility of relapse of malignancies.
Our main concern was to assess the impact of viral hepatitis (B&C) and the efficacy of their therapy on the outcome of ALL.
Eighty seven (87) patients were included in this study and a list of data was collected and completed through surveying their files.
According to these data, they were divided into 3 groups. Group (A): Patients with leukaemia only, Group (B): Patients with leukaemia and having hepatitis, Group (C): Patients with leukaemia, having hepatitis and are receiving an antiviral therapy.